Diligence memo · auto-generated · as of July 2, 2026
Multiply Labs, Inc.
Multiply Labs, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Multiply Labs, Inc. operates in Pharma, based in SAN FRANCISCO, CA, USA. Robotic production capacity for the pharma manufacturing industry
Sub-sector tags: Robotics, pharma, robotics.
Capital & rounds (filed)filed
Multiply Labs, Inc. has raised $41M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2018-10-27.
Most recent recorded round closed around 2023-04-10.
Valuation (modeled)modeled
Provath models Multiply Labs, Inc. at approximately $126M (range $23M–$286M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.60× the median modeled value of Series B Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 3.2 yr ago; this sector typically re-raises about every 16 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 2.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 83% of Pharma peers (310 compared).
Modeled value ranks above 70% of those peers.
Closest niche peers: Switch Therapeutics Inc., March Therapeutics, Inc., Affect Therapeutics, Inc., SPR Therapeutics, Inc., Notch Therapeutics, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.